These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21946421)

  • 1. Aspirin for primary prevention of myocardial infarction: what is the evidence?
    Kappagoda T; Amsterdam E
    J Cardiopulm Rehabil Prev; 2012; 32(1):1-8. PubMed ID: 21946421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The aspirin controversy in primary prevention.
    Raju NC; Eikelboom JW
    Curr Opin Cardiol; 2012 Sep; 27(5):499-507. PubMed ID: 22874127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
    Waltering A; Hemkens L; Florack C
    Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Howard G
    Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
    Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
    Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin.
    McGrath E; O'Conghaile A; Eikelboom JW; Dinneen SF; Oczkowski C; O'Donnell MJ
    Cerebrovasc Dis; 2011; 32(1):22-7. PubMed ID: 21576939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin for primary prevention: yes or no?
    Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
    J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [After the disappointing ASS primary prevention trial. "Holding back in women"].
    Rupprecht HJ
    MMW Fortschr Med; 2005 Mar; 147(12):13. PubMed ID: 15832783
    [No Abstract]   [Full Text] [Related]  

  • 13. [Female, young, healthy. ASS does not protect from myocardial infarct].
    MMW Fortschr Med; 2005 Mar; 147(12):10. PubMed ID: 15832782
    [No Abstract]   [Full Text] [Related]  

  • 14. Aspirin for primary prevention. Doctors and patients should understand potential benefits and risks of aspirin treatment.
    Alkhenizan A
    BMJ; 2000 Dec; 321(7274):1472-3. PubMed ID: 11187951
    [No Abstract]   [Full Text] [Related]  

  • 15. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
    BMJ; 1994 Jan; 308(6921):81-106. PubMed ID: 8298418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management.
    Zuern CS; Lindemann S; Gawaz M
    Semin Thromb Hemost; 2009 Apr; 35(3):295-306. PubMed ID: 19452405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin to prevent heart attack and stroke: what's the right dose?
    Dalen JE
    Am J Med; 2006 Mar; 119(3):198-202. PubMed ID: 16490462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender and stroke: acute phase treatment and prevention.
    Sacco S; Cerone D; Carolei A
    Funct Neurol; 2009; 24(1):45-52. PubMed ID: 19403054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet agents in stroke prevention: acute and long-term treatment strategies.
    Weber R; Weimar C; Diener HC
    Hamostaseologie; 2009 Nov; 29(4):326-33. PubMed ID: 19882077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.